We use cookies on our website. Carry on browsing if you’re happy with this or find out more
Featured article: Kymab to Present Update on Lead Immunocytokine Program KY1043 at Two European Scientific Meetings in November 2019
KY1043, a bifunctional, PD-L1-based, IL-2Rα (CD25)-directed immunocytokine, binds and blocks the activity of PD-L1 on PD-1 and pre...
Read article
Featured article: Kymab and LifeArc enter strategic partnership to discover new medicines using Kymab’s IntelliSelect® technologies
LifeArc will make a US$30 million equity investment in Kymab LifeArc to gain access to IntelliSelect platforms to enhance ...
Read article